- cafead   Sep 12, 2023 at 07:22: PM
via Lyra Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biotechnology company reported a successful Phase 2 study of its LYR-220 drug candidate in the inflammatory sinus disease chronic rhinosinusitis.
article source
article source